Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

Outcomes for follicular lymphoma (FL) have greatly improved, but most patients will
ultimately relapse. High total metabolic tumor volume (TMTV), computed from baseline 18F …

Follicular lymphoma (FL) is generally considered an indolent disorder. With modern day
treatments, long remissions are often achieved both in the front-line and relapsed setting …

In the present study, we screened 84 Follicular Lymphoma patients for somatic mutations
suitable as liquid biopsy MRD biomarkers using a targeted next-generation sequencing …

The incidence of lymphoma has rapidly increased over the last 40 years in Japan, following
a trend that is very similar to that of breast cancer. In particular, the relative frequency of …

We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len)
for patients with relapsed/refractory (R/R) follicular lymphoma (FL) in an open-label …

Non-Hodgkin lymphoma comprises a variety of neoplasms, many of which arise from
germinal center (GC)-experienced B cells. microRNA-28 (miR-28) is a GC-specific miRNA …

Background CART therapy has produced a paradigm shift in the treatment of relapsing FL
patients. Strategies to optimize disease surveillance after these therapies are increasingly …

Background Previous studies reported that early progression of disease (POD) after initial
therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here …

Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT).
However, a small percentage of patients responds poorly to treatment and seems to have a …